Understand the source comparison
Best Research Peptides for Tendon Injury: Mechanism Comparison
BPC-157 Upregulates GH receptors, increases VEGF and collagen Type I synthesis via FAK-paxillin pathway Proliferation (7–21 days) Increased breaking force, accelerated tendon-to-bone healing, improved vascularization Daily (200–500 mcg) Limited human trial dat
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- Upregulates GH receptors, increases VEGF and collagen Type I synthesis via FAK-paxillin pathway
- Proliferation (7–21 days)
- Increased breaking force, accelerated tendon-to-bone healing, improved vascularization
- Daily (200–500 mcg)
- Limited human trial data; most evidence from rodent Achilles tendon models
- TB-500
- Binds G-actin to enhance cell migration; downregulates TGF-beta to reduce fibrosis
- Remodeling (21+ days)
- Reduced scar tissue, improved range of motion, decreased adhesion formation
- Twice weekly loading (2–5 mg), then weekly maintenance
- Anti-fibrotic effect may reduce tensile strength if used too early in healing cascade
- GHK-Cu
- Copper-dependent lysyl oxidase activation for collagen cross-linking; modulates IL-6/TNF-alpha
- Inflammation resolution & remodeling
- Improved collagen organization, enhanced decorin expression, balanced cytokine profile
- Daily (1–3 mg) or topical if formulated
- Requires adequate copper status; effect diminishes if lysyl oxidase is already saturated